Australia's most trusted
source of pharma news
Friday, 21 March 2025
Posted 18 March 2025 AM
A new generation of treatments coming to fruition could rake in combined sales of US$ 30.5 billion in the G7 countries alone in 2030 with four products already either approved for use in Australia or under TGA review.
Clarivate has released a list of 11 Drugs to Watch in 2025 as they begin their blockbuster run and/or transform treatment paradigms over the next five years. These candidates have either been recently launched in the US or are expected to hit the market this year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.